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Abstract
Background: Pulmonary alveolar proteinosis is a rare disease characterized by accumulation of lipoproteinaceous
material within alveoli. There are three clinically distinct forms: congenital, acquired and secondary. Whole lung
lavage is currently the gold standard therapy for severe cases of pulmonary alveolar proteinosis. In Sri Lanka this is
the first reported successful whole lung lavage for a patient with pulmonary alveolar proteinosis.
Case presentation: We describe the case of a 15-year-old Sri Lankan girl who presented with symptoms of
progressive shortness of breath and dry cough for 6 months’ duration. She had a history of exposure to silica in her
household environment. High-resolution computed tomography revealed crazy paving appearance in both lungs
suggestive of pulmonary alveolar proteinosis. An open lung biopsy revealed intra-alveolar granular amphophilic
material which was strongly periodic acid–Schiff positive and diastase resistant, which is consistent with pulmonary
alveolar proteinosis. She was followed up for 2 years with periodical segmental bronchoalveolar lavages which
showed minimal improvement in her symptoms as well as in exercise desaturation. Due to severe dyspnea and
hypoxemia on exertion, she underwent whole lung lavage. It resulted in a marked improvement in her symptoms,
exercise desaturation, and chest X-ray results.
Conclusion: Whole lung lavage was successfully performed for the first time in Sri Lanka for a patient with
pulmonary alveolar proteinosis.
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Background
Pulmonary alveolar proteinosis (PAP) is a rare disease
characterized by the accumulation of a lipoproteinaceous,
eosinophilic, periodic acid–Schiff (PAS) positive material
within the alveoli. The disease was first described by
Rosen et al. in 1958 [1].
There are three different types of PAP: congenital PAP
(2 % of total cases), secondary PAP (less than 10 % of
total cases), and acquired or adult type PAP (90 % of
cases), which is also referred to as primary or idiopathic.
Primary acquired PAP occurs as a disorder of unknown
etiology; it is not associated with any familial predispos-
ition. The secondary form develops in adulthood and is
found in association with high levels of dust exposure
(for example silica, aluminum, titanium, indium-tin oxide)
and hematological malignancies [2]. Macrophage dysfunc-
tion plays an important role in the initiation and propaga-
tion of the disease. The major symptoms are progressive
dyspnea on exertion, cough, fatigue, weight loss, and low
grade fever [3]. Whole lung lavage (WLL) should be con-
sidered in patients with deteriorating lung function and in
cases with progressively worsening symptoms. It is still
the most effective treatment for PAP [4].
In Sri Lanka there are only two previously reported
cases of PAP who were managed with therapeutic-
limited bronchoalveolar lavages (BALs) [5, 6]. We report
the case of an adolescent girl with PAP who underwent
therapeutic WLL, which was the first WLL in Sri Lanka.
Case presentation
Our patient is a Sri Lankan girl; she is currently aged 17
years and has a body mass index (BMI) of 20.34 kg/m2. She
* Correspondence: janithgalhenage@yahoo.co.uk
1Department of Respiratory Medicine, National Hospital for Respiratory
Diseases, Welisara, Sri Lanka
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Galhenage et al. Journal of Medical Case Reports  (2017) 11:62 
DOI 10.1186/s13256-017-1218-2
was previously healthy. She has a significant history of ex-
posure to silica from a stone breaking plant in the vicinity
of her residence.
Development of lung involvement and diagnosis of PAP
In 2014 at 15 years of age, she presented to our clinic
with a 6-month history of progressive dyspnea which
limited her exercise capacity. She noticed that she
started becoming breathless while she walked from the
school gate to the classroom carrying her school bag.
She had a mild nonproductive cough, weight loss, and
poor appetite in addition to breathlessness. She had no
clubbing, cyanosis, or ankle edema and had no evidence
of lymphadenopathy. She was not pale. A respiratory
system examination revealed a respiratory rate of 28
breaths per minute but breath sounds were normal with-
out any added sounds. Cardiovascular, abdominal, and
central nervous system examinations were normal.
Her complete blood count, erythrocyte sedimentation
rate (ESR), and C-reactive protein (CRP) were normal. A
chest X-ray revealed a reticular nodular pattern of bilateral
perihilar distribution (Fig. 1a, b ). A two-dimensional
echocardiogram showed mitral valve prolapse and tricus-
pid valve prolapse. Direct sputum smear microscopy for
acid-fast bacilli was negative. A Gene Xpert test for
Mycobacterium tuberculosis genome detection was nega-
tive. A high-resolution computed tomography (HRCT)
scan revealed diffuse crazy paving appearance in upper,
mid, and lower lobes of both lungs with ground glass
opacity and smooth interlobular septal thickening (Fig. 2).
A pulmonary function test revealed a restrictive pattern:
forced vital capacity (FVC)=1.87 (69.5 %), forced expira-
tory volume in 1 second (FEV1)=1.84 (73.5 %), and FEV1/
FVC=98.3 %.
A 6-minute walk test showed exercise desaturation
from 92 % to 85 %. Her arterial blood gas (ABG) re-
vealed significant hypoxemia while breathing room air:
partial pressure of oxygen (PaO2) 58 mmHg. Her
alveolar-arterial gradient was 45.6 mmHg. A bronchial
wash for cytology showed PAS-positive material; bron-
chial brush cytology showed no malignant cells. Diastase
staining of lavage material and biopsy revealed that the
intra-alveolar material was PAS positive and diastase re-
sistant (Fig. 3a). An open lung biopsy revealed that 60 %
of the alveolar lumina contained granular amphophilic
material with a few histiocytes and pigment material.
The interstitium showed a mild increase in chronic in-
flammatory cells (Fig. 3b). Her lactate dehydrogenase
(LDH) level was 535 U/L (140 to 280). Carbon monox-
ide diffusion capacity (DLCO) was not done prior to
the intervention due to unavailability of resources dur-
ing that time period. Her blood picture showed no
morphological evidence of an hematological malig-
nancy. A human immunodeficiency virus (HIV)
antibody test was negative. A diagnosis of PAP was
confirmed with the HRCT pattern, lung biopsy, and
lavage fluid characteristics.
Two-year follow up
Following diagnosis she was followed up at our respira-
tory out-patient clinic with monitoring of symptoms and
pulmonary function tests on a regular basis. She showed
progressive dyspnea and significant exercise desaturation
during the first month of her follow up; so she under-
went her first therapeutic BAL in March 2014.
A
B
Fig. 1 a Chest radiograph demonstrated reticular nodular pattern of
bilateral perihilar distribution. b A repeated chest radiograph
performed following whole lung lavages demonstrated an
improvement in reticular nodular pattern
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Segmental lavage of left upper, lower, and lingular
lobes was performed under general anesthesia. She
was monitored in our Intensive Care Unit (ICU) post-
procedurally. She underwent seven episodes of thera-
peutic segmental BAL over a period of 1.5 years from
March 2014 to August 2015. At each episode, she was
carefully assessed for fitness for the procedure with
the indication of exercise desaturation and progressive
dyspnea. Although she had mild clinical improvement
in her breathlessness, the improvement in exercise de-
saturation and radiological appearance was minimal,
so we decided to proceed to total lung lavage under
general anesthesia.
WLL treatment
She underwent WLL in the operation theatre. Pulmonary
function tests (spirometry, 6-minute walking distance,
ABG analysis) and radiological assessment (chest X-ray)
were carried out prior to the procedure. For WLL of her
left lung, our patient underwent general anesthesia and
was intubated with a double lumen endotracheal (ET)
tube of 35 gauge. Tracheal and bronchial balloons were
inflated to isolate her two lungs. The correct positioning
of the ET tube was confirmed using a flexible broncho-
scope. The lung isolation was reconfirmed following
immersion of each end of the ET tube in water to look for
air bubbling while the other lung was ventilated. Both
lungs were ventilated for approximately 5 minutes to oxy-
genate our patient adequately before the procedure; then,
single lung ventilation was commenced and was observed
for several minutes to see whether appropriate oxygen-
ation took place during single lung ventilation. After let-
ting her left lung de-gas, warm saline (at 37 °C) run
through a blood warmer, was instilled via the ET tube
until it filled up to the visible level (mouth level) of the
tube. During the first cycle a volume of 300 ml was in-
stilled and chest percussion was performed by a physio-
therapist for 5 minutes. Then the effluent was taken
out by elevating the foot end of the bed and using a low
pressure suction catheter. During this cycle around 200
Fig. 2 High-resolution computed tomography scan revealed diffuse crazy paving appearance in upper, mid, and lower lobes of both lungs with
ground glass opacity and smooth interlobular septal thickening
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ml of the milky effluent was removed. The procedure
was repeated ten times using instillation of warm saline
and removal of the effluent as described above. A total
of 2300 ml of fluid was instilled. WLL was performed
satisfactorily with the removal of an effluent of 1900 ml
which became progressively less opaque. No complica-
tions were observed during or after WLL. In addition
to using warm saline, a warming blanket was used to
maintain the core temperature of our patient during
the procedure.
The milky effluent that came out initially produced a
higher volume of sediment on standing (Fig. 4, Bottle 1).
The height of the sediment reduced towards the last cy-
cles of the procedure (Fig. 4, Bottles 8 and 10). Our pa-
tient was observed in the ICU for approximately 12
hours following the procedure and developed no compli-
cation. She was transferred to a ward following ICU ob-
servation and she was discharged on day 3 following the
procedure. Sequential WLL was done on her right lung,
1 month after the left WLL. A chest X-ray, ABG ana-
lysis, 6-minute walk test, and spirometry were repeated
pre-WLL and post-WLL (Table 1).
Discussion
The incidence of PAP is four times higher in males than
in females and typically presents between 20 and 50
years of age [7]. Up to now, all the three cases found in
Sri Lanka are of female gender, although our case is the
only patient who presented in her adolescence. The
commonest chest X-ray presentations in patients with
PAP are bilateral symmetrical alveolar opacities located
centrally in the mid and lower lung zones, often in a
“batwing” distribution. The chest X-ray of our patient
shows a reticular nodular pattern of bilateral perihilar
distribution. The main features of PAP in HRCT were
present in our patient, constituting thickened intralobu-
lar structures and interlobular septa, with no architec-
tural distortion, often with polygonal shapes, sometimes
called “crazy paving” pattern, and areas of ground glass
opacification with a “geographic” pattern as the diseased
lung is sharply demarcated from the surrounding normal
lung tissue [8]. BAL findings are diagnostic in PAP [9]. It
is opaque or milky in appearance due to the abundant
lipoproteinaceous material, which may settle upon
standing. Histology of lung tissue obtained via trans-
bronchial biopsy or open lung biopsy is a useful adjunct
in the final diagnosis [10] and our patient’s specimen
Fig. 3 a Cytology smear of lavage material shows scattered pinky
brown casts and granular material. Hematoxylin and eosin stain,
100× magnification. Inset Periodic acid–Schiff staining shows these
casts to be periodic acid–Schiff positive. b Open lung biopsy
showed preservation of the alveolar architecture, mild interstitial
chronic inflammation cells, and filling of alveolar spaces with
granular amphophilic material with a few histiocytes and pigment
Fig. 4 The effluent from whole lung lavage which gave an initial
“milky” appearance with a high sediment level (Bottle 1) and
gradually turned less opaque with a lower sediment level (Bottle 10).
The number on each bottle corresponds to the number of the
respective cycle of whole lung lavage
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showed characteristic pathological features. The com-
monest acquired type of PAP is associated with a high
prevalence of anti-granulocyte-macrophage colony-
stimulating factor (anti-GM-CSF) antibody. Several lines
of evidence suggest that diminished anti-GM-CSF pro-
tein or function plays a key role in the pathogenesis of
PAP and is responsible for the observed impairment in
surfactant processing [11]. An anti-GM-CSF antibody
test was not done since it was not available in the local
setting.
Secondary PAP can be associated with three main
clinical settings. First, infection of the lung, most com-
monly with Nocardia asteroides, TB (Tuberculosis),
Mycobacterium avium-intracellulare, or Pneumocystis
carinii. Second, hematologic malignancies and other
conditions that alter the patient’s immune status, for
example, lymphoma, leukemia, or AIDS (Acquired
Immune Deficiency Syndrome). Third, exposure to in-
haled chemicals and minerals, for example, fumes,
dusts, silica [2], aluminum, insecticides, or titanium
[12]. In our patient, infections and malignancies were
excluded with investigations. Since she had a history of
significant exposure to silica, she is most probably a
case of secondary type of PAP caused by inhalation of
silica dust. Silicoproteinosis usually manifests within 3
years of the initial exposure as rapidly progressive
shortness of breath often associated with constitutional
symptoms. The course of the disease is relentlessly pro-
gressive. Most of the reported cases have been fatal
within months [2, 13]. Although 3 years elapsed follow-
ing the symptom onset of our case, the disease progres-
sion is not as rapid as described in the literature.
WLL was first described by Ramirez and colleagues in
1965 and further modified by Wasserman and coworkers
in 1968 [14]. For patients who have moderate to severe
symptoms and hypoxemia, WLL under general
anesthesia via a double-lumen ET tube is the most
widely accepted and effective form of treatment [15].
Specific indications for lung lavage include a definitive
histologic diagnosis and one of the following: resting
PaO2 <65 mmHg (at sea level), alveolar-arterial O2 gra-
dient ≥40 mmHg, measured shunt fraction >10 to 12 %,
or severe dyspnea and hypoxemia at rest or on exercise.
Our patient had most of the above indications for under-
going WLL.
The technique of WLL is well described [16]. In gen-
eral, aliquots of 1 to 1.5 liters of warm saline are re-
quired for each lavage, and a total of approximately 10
to 15 lavages are used for clearing of the lavage effluent
from each lung [17]. Chest percussion during the lavage
procedure significantly increases the recovery of the
lipoproteinaceous material [18]. Complications of WLL
include malpositioning of the ET tube, saline spillover
into the unlavaged ventilated lung, and hydropneu-
mothorax. After WLL, symptoms often improve dramat-
ically; however, long-term follow up is needed since the
clinical outcome is variable. While only one lavage may
be required for a prolonged remission, up to 55 % cases
may need a repeated lavage at 6-month to 12-month in-
tervals [3]. It is often impossible to perform therapeutic
total lung lavage in most patients who are newly diag-
nosed as having PAP due to the above potential compli-
cations and because the patients are usually hypoxemic
and in poor clinical condition. In such cases, multiple
segmental or lobar lavages by fiberoptic bronchoscopy
(FOB) have been reported as a possible alternative to
WLL [19]. Although our patient underwent therapeutic-
ally limited BAL several times under general anesthesia
in the operation theatre, she showed minimal improve-
ment in her clinical, radiological, and pulmonary func-
tion. So we proceeded to WLL, which is the definitive
treatment for PAP. The volume of warm saline needed
to be used for the WLL was comparatively low in our
patient. This is probably due to the small lung volume in
an adolescent patient with a low BMI and chronic inter-
stitial lung disease leading to loss of lung volume. Our
patient showed marked improvement in her symptoms,
pulmonary function, and X-ray results following sequen-
tial WLL of both lungs. However, long-term follow up is
essential to assess the need for repeated WLL.
Conclusion
In conclusion, therapeutic WLL can be successfully per-
formed as a definitive treatment option for a patient
with PAP in Sri Lanka.
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Table 1 Comparison of pulmonary function before and after





ABG pH 7.39 pH 7.37
pO2 58 pO2 87
pCO2 31 pCO2 38
HCO3– 20.3 HCO3– 22.6
Spirometry FVC 1.87 FVC 2.09
FEV1 1.84 FEV1 1.97
Ratio 98.3 % Ratio 95.6 %
DLCO Not done 15.75 (78 %)
Six-minute walk test
(exercise desaturation)
92 %→ 84 % 96 %→ 94 %
Alveolar-arterial gradient 45.6 mmHg 17.2 mmHg
ABG arterial blood gas, DLCO carbon monoxide diffusion capacity, FEV1 forced
expiratory volume in 1 second, FVC forced vital capacity, HCO3– bicarbonate,
pCO2 partial pressure of carbon dioxide, PO2 partial pressure of oxygen
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